CD274 and esophageal adenocarcinoma: A CheckMate 649-based study evaluated the efficacy of nivolumab in combination with chemotherapy versus chemotherapy alone in gastric and esophageal adenocarcinomas and showed a 44% reduction in the risk of death in the nabumab-combination-chemotherapy group as compared to the chemotherapy group in patients with a PD-L1 CPS ≥ 5.